GB201711677D0 - Combination treatment - Google Patents

Combination treatment

Info

Publication number
GB201711677D0
GB201711677D0 GBGB1711677.3A GB201711677A GB201711677D0 GB 201711677 D0 GB201711677 D0 GB 201711677D0 GB 201711677 A GB201711677 A GB 201711677A GB 201711677 D0 GB201711677 D0 GB 201711677D0
Authority
GB
United Kingdom
Prior art keywords
combination treatment
treatment
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1711677.3A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intrabio Ltd
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Priority to GBGB1711677.3A priority Critical patent/GB201711677D0/en
Publication of GB201711677D0 publication Critical patent/GB201711677D0/en
Priority to PL18715909.0T priority patent/PL3600276T3/en
Priority to US16/499,087 priority patent/US11083718B2/en
Priority to FIEP18715909.0T priority patent/FI3600276T3/en
Priority to SI201830944T priority patent/SI3600276T1/en
Priority to ES18715909T priority patent/ES2950452T3/en
Priority to DK18715909.0T priority patent/DK3600276T3/en
Priority to PT187159090T priority patent/PT3600276T/en
Priority to RS20230485A priority patent/RS64304B1/en
Priority to EP23176227.9A priority patent/EP4234022A3/en
Priority to PCT/GB2018/050822 priority patent/WO2018178670A1/en
Priority to EP18715909.0A priority patent/EP3600276B1/en
Priority to HRP20230735TT priority patent/HRP20230735T1/en
Priority to LTEPPCT/GB2018/050822T priority patent/LT3600276T/en
Priority to HUE18715909A priority patent/HUE062729T2/en
Priority to US17/396,064 priority patent/US11690830B2/en
Priority to US18/320,761 priority patent/US20230285373A1/en
Ceased legal-status Critical Current

Links

GBGB1711677.3A 2017-03-28 2017-07-20 Combination treatment Ceased GB201711677D0 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
GBGB1711677.3A GB201711677D0 (en) 2017-07-20 2017-07-20 Combination treatment
HUE18715909A HUE062729T2 (en) 2017-03-28 2018-03-28 Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
RS20230485A RS64304B1 (en) 2017-03-28 2018-03-28 Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
PCT/GB2018/050822 WO2018178670A1 (en) 2017-03-28 2018-03-28 Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
FIEP18715909.0T FI3600276T3 (en) 2017-03-28 2018-03-28 Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
SI201830944T SI3600276T1 (en) 2017-03-28 2018-03-28 Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
ES18715909T ES2950452T3 (en) 2017-03-28 2018-03-28 Betahistine, or a pharmaceutically acceptable salt thereof, and monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
DK18715909.0T DK3600276T3 (en) 2017-03-28 2018-03-28 BETAHISTINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND A MONOAMINOXIDASE INHIBITOR FOR USE IN THE TREATMENT OR PREVENTION OF ONE OR MORE SYMPTOMS OF DIZZINESS IN AN INDIVIDUAL
PT187159090T PT3600276T (en) 2017-03-28 2018-03-28 Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
PL18715909.0T PL3600276T3 (en) 2017-03-28 2018-03-28 Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
EP23176227.9A EP4234022A3 (en) 2017-03-28 2018-03-28 Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
US16/499,087 US11083718B2 (en) 2017-03-28 2018-03-28 Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
EP18715909.0A EP3600276B1 (en) 2017-03-28 2018-03-28 Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
HRP20230735TT HRP20230735T1 (en) 2017-03-28 2018-03-28 Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
LTEPPCT/GB2018/050822T LT3600276T (en) 2017-03-28 2018-03-28 Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
US17/396,064 US11690830B2 (en) 2017-03-28 2021-08-06 Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
US18/320,761 US20230285373A1 (en) 2017-03-28 2023-05-19 Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1711677.3A GB201711677D0 (en) 2017-07-20 2017-07-20 Combination treatment

Publications (1)

Publication Number Publication Date
GB201711677D0 true GB201711677D0 (en) 2017-09-06

Family

ID=59771554

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1711677.3A Ceased GB201711677D0 (en) 2017-03-28 2017-07-20 Combination treatment

Country Status (1)

Country Link
GB (1) GB201711677D0 (en)

Similar Documents

Publication Publication Date Title
IL269371A (en) Treatment methods
GB201608885D0 (en) Treatment
GB201813876D0 (en) Treatment
GB201800546D0 (en) Treatment
GB201711677D0 (en) Combination treatment
GB201718985D0 (en) Treatment
GB201713650D0 (en) Treatment
GB201704949D0 (en) Combination treatment
GB201706955D0 (en) Treatment
GB201814905D0 (en) Treatment
GB201706226D0 (en) Combination therapy
GB201706232D0 (en) Combination therapy
GB201706253D0 (en) Combination therapy
GB201706252D0 (en) Combination therapy
GB201706229D0 (en) Combination therapy
GB201706234D0 (en) Combination therapy
GB201706251D0 (en) Combination therapy
GB201706250D0 (en) Combination therapy
GB201706249D0 (en) Combination therapy
GB201706221D0 (en) Combination therapy
GB201706222D0 (en) Combination therapy
GB201706223D0 (en) Combination therapy
GB201706224D0 (en) Combination therapy
GB201706225D0 (en) Combination therapy
GB201706248D0 (en) Combination therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)